LPL Financial LLC Buys 8,739 Shares of Illumina, Inc. (NASDAQ:ILMN)

LPL Financial LLC boosted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 10.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 91,606 shares of the life sciences company's stock after acquiring an additional 8,739 shares during the quarter. LPL Financial LLC owned 0.06% of Illumina worth $7,268,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of ILMN. Freedom Investment Management Inc. boosted its holdings in shares of Illumina by 3.7% in the 4th quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock worth $382,000 after purchasing an additional 101 shares during the period. Probity Advisors Inc. boosted its holdings in shares of Illumina by 12.2% in the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after purchasing an additional 224 shares during the period. Xponance Inc. boosted its holdings in shares of Illumina by 1.0% in the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock worth $2,123,000 after purchasing an additional 264 shares during the period. Rakuten Securities Inc. boosted its holdings in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after purchasing an additional 270 shares during the period. Finally, Golden State Wealth Management LLC boosted its holdings in shares of Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company's stock worth $42,000 after purchasing an additional 292 shares during the period. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Royal Bank Of Canada lifted their target price on Illumina from $118.00 to $126.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Citigroup cut Illumina from a "hold" rating to a "strong sell" rating and dropped their target price for the stock from $85.00 to $80.00 in a report on Wednesday, July 9th. Scotiabank lowered Illumina from a "sector outperform" rating to a "sector perform" rating and set a $125.00 price target for the company. in a research note on Friday, July 11th. Evercore ISI raised their price target on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Finally, Robert W. Baird raised their price target on Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a research note on Monday, July 28th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $124.58.

Illumina Stock Down 1.4%

NASDAQ ILMN traded down $1.44 on Thursday, reaching $99.67. 893,696 shares of the stock traded hands, compared to its average volume of 2,370,896. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a fifty day moving average price of $96.10 and a 200-day moving average price of $90.64. The company has a market cap of $15.32 billion, a price-to-earnings ratio of 12.61, a PEG ratio of 2.19 and a beta of 1.37. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, topping the consensus estimate of $1.02 by $0.17. The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. Illumina had a return on equity of 28.93% and a net margin of 29.36%. The business's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.36 EPS. As a group, research analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.